摘要:
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention, novel compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
Compounds of the formula: ##STR1## wherein R.sub.1, R.sub.3 and R.sub.4 each independently represents a hydrogen atom or a protecting group;R.sub.2 represents a halogen atom or a group of formula --NR.sub.a R.sub.b (where R.sub.a and R.sub.b, which may be the same or different, each represents a hydrogen atom or an alkyl group; or R.sub.a and R.sub.b may be linked to form, together with the nitrogen atom to which they are attached, a heterocyclic ring which optionally contains a further heteroatom);and their physiological equivalents as well as salts thereof with acids, exhibit antiviral activity against RNA viruses such as Influenza and/or are intermeidates for the preparation of antivirally active compounds.
摘要翻译:下式的化合物:其中R 1,R 3和R 4各自独立地表示氢原子或保护基; R 2表示卤素原子或式-NR a R b的基团(其中R a和R b可以相同或不同,各自表示氢原子或烷基;或者R a和R b可以与 它们所连接的氮原子,任选地含有另外的杂原子的杂环); 和它们的生理等同物以及其与酸的盐,表现出对RNA病毒如流感的抗病毒活性和/或是用于制备抗病毒活性化合物的中间体。
摘要:
The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C1fluoroalkyl; and R5 is: —C(O)—(CH2)n—Ar, —C(O)-Het, —C(O)—C1-6alkyl, —C(O)—C1 fluoroalkyl, —C(O)—(CH2)2—C(O)—NR15bNR15b, —C(O)—CH2—C(O)—NR15bNR15b, —C(O)—NR15b—(CH2)m1—Ar, —C(O)—NR15b—Het, —C(O)—NR15b—C1-6alkyl, —C(O)—NR5aR5b, —S(O)2—(CH2)m2—Ar, —S(O)2-Het, —S(O)2—C1-6alkyl, or —CH2—Ar; or R4 and R5 taken together are —(CH2)p1—, —(CH2)2—X5—(CH2)2—, —C(O)—(CH2)p2—, —C(O)—N(R15)—(CH2)p3—; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.
摘要翻译:本发明提供式(I)化合物或其盐:其中R2是H,C1-3烷基,正丁基,C1-2氟烷基,环丙基,环丁基,(环丙基)甲基,-CN或-CH2OH; R3特别是任选取代的C 4-7环烷基或任选取代的杂环基团(aa),(bb)或(cc); Ra是H,甲基或乙基; Rb是H或甲基; R 4是H,甲基,乙基,正丙基,-C(O)-Me或-C(O)-C 1-6氟烷基; 并且R 5是:-C(O) - (CH 2)n -Ar,-C(O)-Het,-C(O)-C 1-6烷基,-C(O)-C 1氟代烷基,-C(O) (CH 2)2 -C(O)-NR 15 b N R 15 b,-C(O)-CH 2 -C(O)-NR 15 b NR 15 b,-C(O)-NR 15 b - (CH 2)m -Ar,-C(O) C(O)-NR 15 b -C 1-6烷基,-C(O)-NR 5 R 5a,-S(O)2 - (CH 2)m -Ar,-S(O)2 -Het,-S(O) 2-C 1-6烷基或-CH 2 -Ar; 或(R 4)和R 5和R 5一起为 - (CH 2)p1 - , - (CH 2)2 -X 5 - (CH 2)2 - , - - (CH 2)p3-; 或NR4R5为子式(y),(y1),(y2)或(y3)。 本发明提供了化合物作为IV型磷酸二酯酶抑制剂(PDE4)和/或用于治疗和/或预防炎性和/或过敏性疾病如COPD等的用途。
摘要:
The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-3-methyl-5-isoxazolecarboxamide or a salt thereof, such as the compound or a pharmaceutically acceptable salt thereof. The invention also provides the use of the compound or salt as an inhibitor of phosphodiesterase type IV (PDE4.
摘要:
The present invention relates to compounds of formula (I) ##STR1## and salts and metabolically labile esters thereof; wherein R is a 5 or 6 membered nitrogen containing heteroaryl group, which heteroaryl group optionally contains 1 or 2 additional heteroatoms selected from nitrogen, oxygen or sulphur and said heteroaryl group is linked to the alkylene chain (CH.sub.2)n via a nitrogen atom in the heteroaryl group; n is an integer from 2 to 4, to processes for their preparation and to their use as antibacterial agents.